Latest Stock Advice
It is important to note that some types of investments provide more security than others. Investors seeking safe investment options should look for well-established companies with hidden assets among other key characteristics.
Sun Life Financial Inc. and Manulife Financial Corp. each offers a combination of solid earnings growth, ongoing share repurchases, and impressive dividend yields.
Top pick Yum Brands Inc. gives you sales growth, steady EPS growth, and a solid dividend
Nutrien Ltd. offers exposure to potash and nitrogen prices, a stable retail base and strong profitability.
Become a Successful Investor
Tax shelters in Canada aim to reduce or eliminate your tax liability, they are great ways for Canadian investors to cut their tax bills.
In some ways, stock buyback benefits are better than dividends. In particular, they give you a tax-deferral option that you don’t get with cash dividends.
GENERAL MILLS INC., $57.43, New York symbol GIS, is one of the world’s largest food makers. Top brands include Big G (cereal), Green Giant (canned and frozen vegetables), Pillsbury (baking dough), Old El Paso (tacos), Progresso (soups and salads) and Yoplait (yogourt). In its fiscal 2016 first quarter, which ended August 30, 2015, General Mills earned $426.6 million, up 23.6% from $345.2 million a year earlier. Earnings per share gained 25.4%, to $0.69 from $0.55, on fewer shares outstanding. Without unusual items, such as gains and losses on hedging contracts General Mills uses to lock in certain ingredient prices, earnings per share rose 29.5%, to $0.79 from $0.61. That beat the consensus estimate of $0.69....
Beware of penny stock promoters. They are usually more interested in boosting their stocks than building their business.
Drug stocks operate under distinct negatives. For example, new drugs take years to win regulatory approval, if ever. As well, they face increasing litigation and aggressive competition from generics. However, we feel Pfizer will continue to overcome these challenges. Its high research spending is letting it replace drugs whose patents are expiring. The company also recently acquired Hospira, an innovative firm that’s successfully developing and selling a new class of drugs called biosimilars. These treatments give Pfizer a new source of growth to offset sales lost to generic drug makers. The stock is up 65.0% for us since we first recommended it in our July 2011 issue, but we feel it still has plenty of gains ahead....